HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New staff chief for von E

This article was originally published in The Rose Sheet

Executive Summary

Three months after moving to FDA from the American Pharmacists Association (APA) Susan Winckler is named acting chief of staff for FDA Commissioner Andrew von Eschenbach. Winckler, an attorney, joined FDA in September 2006 as policy communications director in the commissioner's Office of Policy & Planning, where she was the point person for constituent communications and policy development relevant to FDA advisory committees. Starting in January 2007, Winckler will coordinate staff activities and be the principal liaison to HHS. The Senate confirmed von Eschenbach as FDA commissioner Dec. 7 (1"The Rose Sheet" Dec. 11, 2006, p. 10)...

You may also be interested in...



Acting Commissioner Von Eschenbach Made Permanent In Time For New Year

Andrew von Eschenbach can delete "acting" from his office nameplate; the Senate confirmed him as FDA commissioner Dec. 7 by a comfortable 80-11 margin, ending months of "holds" on the vote and opposition to his nomination from both sides of the aisle

Keeping Track: Quick Trips From Breakthrough Designation To Market

Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.

Breakthrough Therapy Designations: Phase II Data Is Sweet Spot For US FDA Award

Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.

UsernamePublicRestriction

Register

RS014420

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel